Bachem, a Bubendorf, Switzerland-headquartered CDMO of peptides and oligonucleotides, is proceeding with a billion-dollar plus investment plan to increase manufacturing capacity across its sites, including new facilities. Dr. Torsten Wöhr, Chief Commercial Officer, Bachem, provided an update at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week. 

Bachem is pursuing an investment program across its sites to expand capacity. The company is constructing a large-scale facility for the manufacture of peptides and oligonucleotides at its site in Bubendorf, Switzerland. The commissioning of the new large-scale peptide and oligonucleotide production plant in Bubendorf is planned for 2024 with the first phase operational in 2024 and a second phase operational in 2026.  By 2030, a further production site is planned at a new site in Sisslerfeld in the municipality of Eiken, Canton of Aargau, Switzerland. In October 2022, Bachem announced its purchase of land for the new site in Sisslerfeld/Eiken. In all, Bachem is planning investments of CHF 550 million ($600 million) at its headquarters site in Bubendorf and CHF 750 million ($819 million) for the new site in Sisslerfeld/Eiken. Bachem is also investing in capacity expansions across its global manufacturing network at its sites in the following: Vionnaz, Switzerland; Torrance, California; Vista, California; and St. Helens, UK. 

These investments support the company’s growth strategies. In 2022, the company posted revenues of CHF 532 million ($581 million), which represented a doubling of revenues over the past five years. Overall, the company has 170 R&D projects and more than 40 commercial projects and 1,900 employees worldwide.